Supplementary Table 2.
Univariate analysis of risk factors for OS and DFS in all patients.
| OS | DFS | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| ATG vs non-ATG | 0.683 | 0.323–1.444 | 0.318 | 1.411 | 0.749–2.657 | 0.287 |
| Recipient age (≥ median vs < median) | 1.324 | 0.638–2.751 | 0.451 | 1.214 | 0.641–2.297 | 0.552 |
| Donor age (≥ median vs < median) | 0.992 | 0.485–2.031 | 0.983 | 1.147 | 0.611–2.155 | 0.669 |
| Donor-recipient gender match | ||||||
| Female to male vs others | 0.909 | 0.416–1.985 | 0.810 | 0.965 | 0.489–1.905 | 0.918 |
| Donor-recipient ABO match | ||||||
| Mismatch vs match | 1.196 | 0.575–2.488 | 0.631 | 1.415 | 0.751–2.667 | 0.283 |
| Diagnosis (ALL vs others) | 0.979 | 0.434–2.205 | 0.959 | 1.463 | 0.749–2.856 | 0.265 |
| Time interval between diagnosis and HSCT | ||||||
| ≥6 m vs <6 m | 0.559 | 0.266–1.176 | 0.125 | 0.593 | 0.311–1.133 | 0.114 |
| Cytogenetic risk | ||||||
| High vs favorable/intermediate | 0.593 | 0.243–1.452 | 0.253 | 1.135 | 0.575–2.242 | 0.715 |
| Disease status at HSCT | ||||||
| Untreated/refractory/relapsed vs CR | 1.351 | 0.579–3.151 | 0.486 | 1.262 | 0.599–2.661 | 0.540 |
| Disease risk index | ||||||
| High/very high vs low/intermediate | 0.821 | 0.366–1.846 | 0.634 | 1.341 | 0.696–2.583 | 0.381 |
| MNC (≥ median vs <median) | 0.875 | 0.427–1.794 | 0.716 | 0.881 | 0.469–1.653 | 0.693 |
| CD34 (≥ median vs <median) | 1.018 | 0.496–2.092 | 0.960 | 1.402 | 0.742–2.648 | 0.298 |
ATG – anti-thymocyte globulin; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells; OS – overall survival; DFS – disease-free survival.